Oracle stock price target raised to $400 from $250 at Global Equities
Investing.com - Piper Sandler has reiterated an Overweight rating and $449.00 price target on Alnylam Pharmaceuticals (NASDAQ:ALNY), currently valued at $58.5 billion, following impressive 48-month follow-up data from the Phase III HELIOS-B trial presented at the European Society of Cardiology (ESC) Congress. According to InvestingPro data, 13 analysts have recently revised their earnings estimates upward, with price targets ranging from $236 to $570.
The data showed that AMVUTTRA reduced the risk of all-cause mortality or cardiovascular events by 37% overall and by 42% in patients not receiving tafamidis. This strong performance has driven rapid uptake of AMVUTTRA in ATTR-cardiomyopathy patients.
Alnylam has increased its ATTR revenue guidance to $2.175-2.275 billion for 2025, with Piper Sandler projecting potential growth to $3.5 billion in 2026. The company also presented Phase II KARDIA-3 data on zilebesiran in hypertension at ESC.
Alnylam and partner Roche expect to initiate the Phase III ZENITH cardiovascular outcomes trial for zilebesiran by the end of 2025. Separately, Regeneron plans to submit an NDA for cemdisiran in the first quarter of 2026, which could generate regulatory milestones and double-digit royalties up to 15% for Alnylam.
The company achieved Non-GAAP profitability and ended the second quarter of 2025 with $2.9 billion in cash and $1.0 billion in convertible debt.
In other recent news, Alnylam Pharmaceuticals reported second-quarter earnings that significantly exceeded analyst expectations. The company posted adjusted earnings of $0.32 per share for the quarter ending June 30, 2025, surpassing the consensus estimate of -$0.59. Revenue reached $773.7 million, well above the projected $643.2 million, with a 64% year-over-year increase in total net product revenues to $672.2 million, largely driven by AMVUTTRA’s strong performance in ATTR cardiomyopathy. Additionally, Oppenheimer upgraded Alnylam’s stock to Outperform, citing Amvuttra’s robust sales, which generated approximately $150 million in its first full quarter, far exceeding both the firm’s estimate of $10 million and the consensus forecast of $17 million. Wolfe Research also upgraded Alnylam to Peerperform, highlighting the company’s better-than-expected patient acquisition capabilities. Truist Securities maintained its Buy rating and a $459.00 price target, anticipating upcoming clinical data presentation at the European Society of Cardiology conference. These developments indicate significant activity and interest in Alnylam Pharmaceuticals from both analysts and investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.